IM8, the health drink startup co-founded by David Beckham and Danny Yeung, has secured a $1 billion investment from General Catalyst’s Customer Value Fund (CVF). This funding approach is distinctive, as CVF provides capital through loans with unconventional repayment terms, rather than traditional equity investments. Consequently, General Catalyst does not acquire an ownership stake in IM8, preserving the startup’s existing ownership structure.
IM8 offers a vitamin drink formulated with compounds associated with promoting longevity, including açai fruit extract and Coenzyme Q10. The product is available to consumers through a subscription model. The substantial investment from CVF is intended to cover up to 70% of IM8’s customer acquisition expenses. In return, General Catalyst will receive a capped share of the revenue generated from these customers, calculated by multiplying the revenue by a predetermined gross-margin assumption. Once the investment is recouped and the revenue share cap is reached, all subsequent revenue from these customers will revert to IM8’s parent company, Prenetics.
General Catalyst’s CVF has previously engaged in similar funding arrangements with other companies. For instance, in May 2025, Grammarly secured a $1 billion investment from CVF, which preceded its acquisition of Superhuman. This pattern indicates a strategic focus by General Catalyst on supporting companies with predictable revenue streams and scalable growth plans through non-dilutive financing methods.
The collaboration between IM8 and General Catalyst’s CVF underscores a growing trend in venture financing, where startups seek substantial capital without relinquishing equity. This model is particularly advantageous for companies like IM8 that have clear revenue trajectories and require significant investment to accelerate growth. As the market for health and wellness products continues to expand, IM8’s ability to leverage this funding effectively could position it as a formidable player in the industry.
